vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Xperi Inc. (XPER). Click either name above to swap in a different company.

Xperi Inc. is the larger business by last-quarter revenue ($116.5M vs $75.1M, roughly 1.6× MEDIFAST INC). On growth, Xperi Inc. posted the faster year-over-year revenue change (-4.8% vs -36.9%). Xperi Inc. produced more free cash flow last quarter ($1.2M vs $-6.6M). Over the past eight quarters, Xperi Inc.'s revenue compounded faster (-1.0% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Xperi Inc. is an American multinational technology company headquartered in San Jose, California, that develops software for consumer electronics and connected cars, as well as media platforms for video service over broadband. The company is organized into four business units: Pay TV, Consumer Electronics, Connected Car, and Media Platform. Xperi's brands include DTS, HD Radio, and TiVo.

MED vs XPER — Head-to-Head

Bigger by revenue
XPER
XPER
1.6× larger
XPER
$116.5M
$75.1M
MED
Growing faster (revenue YoY)
XPER
XPER
+32.1% gap
XPER
-4.8%
-36.9%
MED
More free cash flow
XPER
XPER
$7.8M more FCF
XPER
$1.2M
$-6.6M
MED
Faster 2-yr revenue CAGR
XPER
XPER
Annualised
XPER
-1.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
XPER
XPER
Revenue
$75.1M
$116.5M
Net Profit
$-17.1M
Gross Margin
69.4%
Operating Margin
-10.4%
-12.7%
Net Margin
-14.7%
Revenue YoY
-36.9%
-4.8%
Net Profit YoY
-137.0%
EPS (diluted)
$-1.64
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
XPER
XPER
Q4 25
$75.1M
$116.5M
Q3 25
$89.4M
$111.6M
Q2 25
$105.6M
$105.9M
Q1 25
$115.7M
$114.0M
Q4 24
$119.0M
$122.4M
Q3 24
$140.2M
$132.9M
Q2 24
$168.6M
$119.6M
Q1 24
$174.7M
$118.8M
Net Profit
MED
MED
XPER
XPER
Q4 25
$-17.1M
Q3 25
$-2.3M
$-6.1M
Q2 25
$2.5M
$-14.8M
Q1 25
$-772.0K
$-18.4M
Q4 24
$46.2M
Q3 24
$1.1M
$-16.8M
Q2 24
$-8.2M
$-30.3M
Q1 24
$8.3M
$-13.1M
Gross Margin
MED
MED
XPER
XPER
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
XPER
XPER
Q4 25
-10.4%
-12.7%
Q3 25
-4.6%
-1.2%
Q2 25
-1.0%
-10.5%
Q1 25
-1.1%
-14.4%
Q4 24
0.6%
-11.7%
Q3 24
1.5%
-14.0%
Q2 24
-4.7%
-18.3%
Q1 24
4.5%
-27.2%
Net Margin
MED
MED
XPER
XPER
Q4 25
-14.7%
Q3 25
-2.5%
-5.5%
Q2 25
2.3%
-14.0%
Q1 25
-0.7%
-16.1%
Q4 24
37.8%
Q3 24
0.8%
-12.6%
Q2 24
-4.8%
-25.3%
Q1 24
4.8%
-11.0%
EPS (diluted)
MED
MED
XPER
XPER
Q4 25
$-1.64
$-0.37
Q3 25
$-0.21
$-0.13
Q2 25
$0.22
$-0.32
Q1 25
$-0.07
$-0.41
Q4 24
$0.08
$1.02
Q3 24
$0.10
$-0.37
Q2 24
$-0.75
$-0.67
Q1 24
$0.76
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
XPER
XPER
Cash + ST InvestmentsLiquidity on hand
$167.3M
$96.8M
Total DebtLower is stronger
$27.7M
Stockholders' EquityBook value
$198.9M
$414.1M
Total Assets
$248.0M
$615.8M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
XPER
XPER
Q4 25
$167.3M
$96.8M
Q3 25
$173.5M
$96.8M
Q2 25
$162.7M
$95.1M
Q1 25
$164.6M
$88.0M
Q4 24
$162.3M
$130.6M
Q3 24
$170.0M
$72.7M
Q2 24
$163.5M
$92.5M
Q1 24
$156.4M
$95.2M
Total Debt
MED
MED
XPER
XPER
Q4 25
$27.7M
Q3 25
$27.7M
Q2 25
$27.7M
Q1 25
$27.7M
Q4 24
$27.7M
Q3 24
$27.7M
Q2 24
$27.7M
Q1 24
$27.7M
Stockholders' Equity
MED
MED
XPER
XPER
Q4 25
$198.9M
$414.1M
Q3 25
$214.7M
$421.0M
Q2 25
$216.0M
$419.8M
Q1 25
$211.0M
$418.9M
Q4 24
$210.1M
$429.1M
Q3 24
$207.3M
$377.4M
Q2 24
$205.3M
$388.7M
Q1 24
$211.0M
$399.1M
Total Assets
MED
MED
XPER
XPER
Q4 25
$248.0M
$615.8M
Q3 25
$268.2M
$628.8M
Q2 25
$269.3M
$629.2M
Q1 25
$280.0M
$633.5M
Q4 24
$284.2M
$667.8M
Q3 24
$291.2M
$616.2M
Q2 24
$293.5M
$619.2M
Q1 24
$302.8M
$630.4M
Debt / Equity
MED
MED
XPER
XPER
Q4 25
0.07×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.07×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
XPER
XPER
Operating Cash FlowLast quarter
$-5.3M
$4.1M
Free Cash FlowOCF − Capex
$-6.6M
$1.2M
FCF MarginFCF / Revenue
-8.8%
1.0%
Capex IntensityCapex / Revenue
1.8%
2.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$-5.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
XPER
XPER
Q4 25
$-5.3M
$4.1M
Q3 25
$12.1M
$7.5M
Q2 25
$-3.4M
$10.1M
Q1 25
$3.4M
$-22.3M
Q4 24
$-4.9M
$1.2M
Q3 24
$9.1M
$-4.6M
Q2 24
$13.1M
$-2.1M
Q1 24
$7.3M
$-49.8M
Free Cash Flow
MED
MED
XPER
XPER
Q4 25
$-6.6M
$1.2M
Q3 25
$10.8M
$6.7M
Q2 25
$-4.8M
$9.5M
Q1 25
$1.9M
$-23.3M
Q4 24
$-7.2M
$-510.0K
Q3 24
$7.7M
$-5.6M
Q2 24
$11.1M
$-2.6M
Q1 24
$5.4M
$-51.6M
FCF Margin
MED
MED
XPER
XPER
Q4 25
-8.8%
1.0%
Q3 25
12.0%
6.0%
Q2 25
-4.5%
9.0%
Q1 25
1.6%
-20.5%
Q4 24
-6.1%
-0.4%
Q3 24
5.5%
-4.2%
Q2 24
6.6%
-2.2%
Q1 24
3.1%
-43.4%
Capex Intensity
MED
MED
XPER
XPER
Q4 25
1.8%
2.5%
Q3 25
1.5%
0.7%
Q2 25
1.3%
0.5%
Q1 25
1.3%
0.9%
Q4 24
1.9%
1.4%
Q3 24
1.0%
0.8%
Q2 24
1.1%
0.4%
Q1 24
1.1%
1.6%
Cash Conversion
MED
MED
XPER
XPER
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
0.03×
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

XPER
XPER

Pay TV$56.2M48%
Connected Car$31.3M27%
Consumer Electronics$17.2M15%
Media Platform$11.8M10%

Related Comparisons